K Number
K244008
Device Name
Spectral CT
Date Cleared
2025-05-16

(141 days)

Product Code
Regulation Number
892.1750
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The Spectral CT system is a Computed Tomography X-ray system intended to produce cross-sectional images of the body by computer reconstruction of X-ray transmission data taken at different angles and planes. This device may include signal analysis and display equipment, patient and equipment support, component parts, and accessories. The Spectral CT system acquires one CT dataset – composed of data from a higher-energy detected X-ray spectrum and a lower- energy detected X-ray spectrum. The two spectra may be used to analyze the differences in the energy dependence of the attenuation coefficient of different materials. This allows for the generation of images at energies selected from the available spectrum and to provide information about the chemical composition of the body materials and/or contrast agents. Additionally, materials analysis provides for the quantification and graphical display of attenuation, material density, and effective atomic number. This information may be used by a trained healthcare professional as a diagnostic tool for the visualization and analysis of anatomical and pathological structures in patients of all ages, and to be used for diagnostic imaging in radiology, interventional radiology, and cardiology and in oncology as part of treatment preparation and radiation therapy planning. The Extended field of view images and respiratory correlated scanning (4DCT) are for treatment preparation and radiation therapy planning/simulation usage only. This device is indicated for head, whole body, cardiac and vascular X-ray Computed Tomography applications in patients of all ages. The system is also intended to be used for low dose CT lung cancer screening for the early detection of lung nodules that may represent cancer*. The screening must be performed within the established inclusion criteria of programs / protocols that have been approved and published by either a governmental body or professional medical society. *Please refer to clinical literature, including the results of the National Lung Screening Trial (N Engl. J Med 2011; 365:395-409) and subsequent literature, for further information.
Device Description
Spectral CT system is a whole-body computed tomography (CT) X-ray system featuring a continuously rotating X-ray tube and detectors gantry, and multi slice capability. The acquired X-ray transmission data is reconstructed by computer into cross-sectional images of the body taken at different angles and planes. This system also includes signals analysis and display equipment, patient and equipment support, components, and accessories. The Spectral CT system acquires one CT dataset – composed of data from a higher energy detected X-ray spectrum and a lower- energy detected X-ray spectrum. The two spectra may be used to analyze the differences in the energy dependence of the attenuation coefficient of different materials. This allows for the generation of images at energies selected from the available spectrum and provides information about the chemical composition of the body materials and/or contrast agents. Additionally, materials analysis provides for the quantification and graphical display of attenuation, material density, and effective atomic number. The Spectral CT system consists of three main components – a scanner system that includes a rotating gantry, a movable patient couch, and an operator console for control and image reconstruction; a Spectral Reconstruction System; and a Spectral CT Viewer. On the gantry, the main active components are the X-ray high voltage (HV) power supply, the X-ray tube, and the detection system. The fundamental design and characteristics of the main components used in the proposed Spectral CT system are identical to the currently marketed primary predicate device, Spectral CT system (K203020).
More Information

Not Found

No.
The document describes a Computed Tomography (CT) system that performs image reconstruction and signal analysis. While image processing is involved, there is no mention of AI, deep neural networks (DNN), or machine learning (ML) being used for these functions. The description focuses on traditional CT technology and data reconstruction methods.

No.
The device is a diagnostic imaging system and is not described as providing treatment.

Yes

The "Intended Use / Indications for Use" section explicitly states that the information provided by the device "may be used by a trained healthcare professional as a diagnostic tool for the visualization and analysis of anatomical and pathological structures in patients of all ages, and to be used for diagnostic imaging".

No

The device description clearly outlines hardware components such as an X-ray tube, detectors gantry, movable patient couch, and an operator console, indicating it is a physical medical imaging system, not solely software.

No.
The device is a Computed Tomography X-ray system that produces cross-sectional images of the body using X-ray transmission data. This is an in-vivo imaging device, not an in-vitro diagnostic device which analyzes specimens obtained from the human body.

N/A

Intended Use / Indications for Use

The Spectral CT system is a Computed Tomography X-ray system intended to produce cross-sectional images of the body by computer reconstruction of X-ray transmission data taken at different angles and planes. This device may include signal analysis and display equipment, patient and equipment support, component parts, and accessories.

The Spectral CT system acquires one CT dataset – composed of data from a higher-energy detected X-ray spectrum and a lower- energy detected X-ray spectrum. The two spectra may be used to analyze the differences in the energy dependence of the attenuation coefficient of different materials. This allows for the generation of images at energies selected from the available spectrum and to provide information about the chemical composition of the body materials and/or contrast agents.

Additionally, materials analysis provides for the quantification and graphical display of attenuation, material density, and effective atomic number.

This information may be used by a trained healthcare professional as a diagnostic tool for the visualization and analysis of anatomical and pathological structures in patients of all ages, and to be used for diagnostic imaging in radiology, interventional radiology, and cardiology and in oncology as part of treatment preparation and radiation therapy planning. The Extended field of view images and respiratory correlated scanning (4DCT) are for treatment preparation and radiation therapy planning/simulation usage only.

This device is indicated for head, whole body, cardiac and vascular X-ray Computed Tomography applications in patients of all ages.

The system is also intended to be used for low dose CT lung cancer screening for the early detection of lung nodules that may represent cancer*. The screening must be performed within the established inclusion criteria of programs / protocols that have been approved and published by either a governmental body or professional medical society.

*Please refer to clinical literature, including the results of the National Lung Screening Trial (N Engl. J Med 2011; 365:395-409) and subsequent literature, for further information.

Product codes

JAK

Device Description

Spectral CT system is a whole-body computed tomography (CT) X-ray system featuring a continuously rotating X-ray tube and detectors gantry, and multi slice capability. The acquired X-ray transmission data is reconstructed by computer into cross-sectional images of the body taken at different angles and planes. This system also includes signals analysis and display equipment, patient and equipment support, components, and accessories.

The Spectral CT system acquires one CT dataset – composed of data from a higher energy detected X-ray spectrum and a lower- energy detected X-ray spectrum. The two spectra may be used to analyze the differences in the energy dependence of the attenuation coefficient of different materials. This allows for the generation of images at energies selected from the available spectrum and provides information about the chemical composition of the body materials and/or contrast agents. Additionally, materials analysis provides for the quantification and graphical display of attenuation, material density, and effective atomic number.

The Spectral CT system consists of three main components – a scanner system that includes a rotating gantry, a movable patient couch, and an operator console for control and image reconstruction; a Spectral Reconstruction System; and a Spectral CT Viewer. On the gantry, the main active components are the X-ray high voltage (HV) power supply, the X-ray tube, and the detection system.

The fundamental design and characteristics of the main components used in the proposed Spectral CT system are identical to the currently marketed primary predicate device, Spectral CT system (K203020).

Mentions image processing

Yes

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Computed Tomography X-ray

Anatomical Site

head, whole body, cardiac and vascular, lung

Indicated Patient Age Range

patients of all ages

Intended User / Care Setting

trained healthcare professional / radiology, interventional radiology, cardiology, oncology (treatment preparation and radiation therapy planning)

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies

Non-clinical performance testing was performed on the proposed Spectral CT system, demonstrating compliance with international and FDA recognized consensus standards and FDA guidance documents. Design verification and validation tests were conducted, including phantom-based image quality (IQ) testing (assessing noise, resolution, and artifacts), a representative clinical image assessment, and comparison of performance data against internal performance requirements. All validation tests met acceptance criteria. This data supports the safety, effectiveness, and substantial equivalence of the device.

Key Metrics

Not Found

Predicate Device(s)

K203020, K240844

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 892.1750 Computed tomography x-ray system.

(a)
Identification. A computed tomography x-ray system is a diagnostic x-ray system intended to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data from the same axial plane taken at different angles. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.

FDA 510(k) Clearance Letter - Spectral CT System

Page 1

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov

Doc ID # 04017.07.05

May 16, 2025

Philips Medical Systems Technologies Ltd.
℅ Carmit Shmuel
Regulatory Affairs Manager and Site Lead
Advanced Technology Center, Building 34, MATAM
HAIFA, 3100202
ISRAEL

Re: K244008
Trade/Device Name: Spectral CT
Regulation Number: 21 CFR 892.1750
Regulation Name: Computed tomography x-ray system
Regulatory Class: Class II
Product Code: JAK
Dated: February 3, 2025
Received: April 14, 2025

Dear Carmit Shmuel:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Page 2

K244008 - Carmit Shmuel Page 2

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-

Page 3

K244008 - Carmit Shmuel Page 3

assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Lu Jiang

Lu Jiang, Ph.D.
Assistant Director
Diagnostic X-Ray Systems Team
DHT8B: Division of Radiological Imaging
Devices and Electronic Products
OHT8: Office of Radiological Health
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

Page 4

FORM FDA 3881 (8/23) Page 1 of 1

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120
Expiration Date: 07/31/2026
See PRA Statement below.

510(k) Number (if known): K244008
Device Name: Spectral CT

Indications for Use (Describe)

The Spectral CT system is a Computed Tomography X-ray system intended to produce cross-sectional images of the body by computer reconstruction of X-ray transmission data taken at different angles and planes. This device may include signal analysis and display equipment, patient and equipment support, component parts, and accessories.

The Spectral CT system acquires one CT dataset – composed of data from a higher-energy detected X-ray spectrum and a lower- energy detected X-ray spectrum. The two spectra may be used to analyze the differences in the energy dependence of the attenuation coefficient of different materials. This allows for the generation of images at energies selected from the available spectrum and to provide information about the chemical composition of the body materials and/or contrast agents.

Additionally, materials analysis provides for the quantification and graphical display of attenuation, material density, and effective atomic number.

This information may be used by a trained healthcare professional as a diagnostic tool for the visualization and analysis of anatomical and pathological structures in patients of all ages, and to be used for diagnostic imaging in radiology, interventional radiology, and cardiology and in oncology as part of treatment preparation and radiation therapy planning. The Extended field of view images and respiratory correlated scanning (4DCT) are for treatment preparation and radiation therapy planning/simulation usage only.

This device is indicated for head, whole body, cardiac and vascular X-ray Computed Tomography applications in patients of all ages.

The system is also intended to be used for low dose CT lung cancer screening for the early detection of lung nodules that may represent cancer*. The screening must be performed within the established inclusion criteria of programs / protocols that have been approved and published by either a governmental body or professional medical society.

*Please refer to clinical literature, including the results of the National Lung Screening Trial (N Engl. J Med 2011; 365:395-409) and subsequent literature, for further information.

Based on the information provided above, the proposed Spectral CT system is considered substantially equivalent to the currently marketed primary predicate device, Spectral CT system (K203020), in terms of Indications for Use.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.


This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

Page 5

K244008 510(k) Summary

This 510(k) summary of safety and effectiveness information is prepared in accordance with 21 CFR §807.92.

Date Prepared: February 03, 2025

Manufacturer: Philips Medical Systems Nederland B.V.
Veenpluis 6,
5684 PC BEST
The Netherlands
Establishment Registration Number: 3015777306

Primary Contact Person:
Rachel Shalit
Regulatory Affairs Specialist
Phone: +972-54-9988057
E-Mail: rachel.shalit@philips.com

Secondary Contact Person:
Carmit Shmuel
Regulatory Affairs Manager and Site Lead
Phone: +972-54-2109054
E-Mail: Carmit.Shmuel@philips.com

Device Information

  • Trade Name: Spectral CT
  • Common name: Computed Tomography X-ray System
  • Classification Name: Computed Tomography X-ray System
  • Classification Regulation: 21CFR 892.1750
  • Classification Panel: Radiology
  • Device Class: II
  • Product Code: JAK

Primary Predicate Device

  • Trade Name: Spectral CT
  • Manufacturer: Philips Medical Systems Nederland B.V.
  • 510(k) Clearance: K203020
  • Classification Name: Computed Tomography X-ray System
  • Classification Regulation: 21 CFR 892.1750
  • Classification Panel: Radiology
  • Device Class: Class II
  • Product Code: JAK

Secondary Predicate Device

  • Trade Name: Spectral CT 7500 RT
  • Manufacturer: Philips Medical Systems Nederland B.V.
  • 510(k) Clearance: K240844
  • Classification Name: Computed Tomography X-ray System
  • Classification Regulation: 21 CFR 892.1750
  • Classification Panel: Radiology
  • Device Class: Class II
  • Product Code: JAK

Page 6

Device Description

Spectral CT system is a whole-body computed tomography (CT) X-ray system featuring a continuously rotating X-ray tube and detectors gantry, and multi slice capability. The acquired X-ray transmission data is reconstructed by computer into cross-sectional images of the body taken at different angles and planes. This system also includes signals analysis and display equipment, patient and equipment support, components, and accessories.

The Spectral CT system acquires one CT dataset – composed of data from a higher energy detected X-ray spectrum and a lower- energy detected X-ray spectrum. The two spectra may be used to analyze the differences in the energy dependence of the attenuation coefficient of different materials. This allows for the generation of images at energies selected from the available spectrum and provides information about the chemical composition of the body materials and/or contrast agents. Additionally, materials analysis provides for the quantification and graphical display of attenuation, material density, and effective atomic number.

The Spectral CT system consists of three main components – a scanner system that includes a rotating gantry, a movable patient couch, and an operator console for control and image reconstruction; a Spectral Reconstruction System; and a Spectral CT Viewer. On the gantry, the main active components are the X-ray high voltage (HV) power supply, the X-ray tube, and the detection system.

The fundamental design and characteristics of the main components used in the proposed Spectral CT system are identical to the currently marketed primary predicate device, Spectral CT system (K203020).

Indications for Use

The Spectral CT system is a Computed Tomography X-ray system intended to produce cross-sectional images of the body by computer reconstruction of X-ray transmission data taken at different angles and planes. This device may include signal analysis and display equipment, patient and equipment support, component parts, and accessories.

The Spectral CT system acquires one CT dataset – composed of data from a higher-energy detected X-ray spectrum and a lower- energy detected X-ray spectrum. The two spectra may be used to analyze the differences in the energy dependence of the attenuation coefficient of different materials. This allows for the generation of images at energies selected from the available spectrum and to provide information about the chemical composition of the body materials and/or contrast agents.

Additionally, materials analysis provides for the quantification and graphical display of attenuation, material density, and effective atomic number.

This information may be used by a trained healthcare professional as a diagnostic tool for the visualization and analysis of anatomical and pathological structures in patients of all ages, and to be used for diagnostic imaging in radiology, interventional radiology, and cardiology and in oncology as part of treatment preparation and radiation therapy planning. The Extended field of view images and respiratory correlated scanning (4DCT) are for treatment preparation and radiation therapy planning/simulation usage only.

This device is indicated for head, whole body, cardiac and vascular X-ray Computed Tomography applications in patients of all ages.

The system is also intended to be used for low dose CT lung cancer screening for the early detection of lung nodules that may represent cancer*. The screening must be performed within the established inclusion criteria of programs / protocols that have been approved and published by either a governmental body or professional medical society.

*Please refer to clinical literature, including the results of the National Lung Screening Trial (N Engl. J Med 2011; 365:395-409) and subsequent literature, for further information.

Based on the information provided above, the proposed Spectral CT system is considered substantially equivalent to the currently marketed primary predicate device, Spectral CT system (K203020), in terms of Indications for Use.

Page 7

Technological Characteristics

The proposed Spectral CT system consists of three main components – a scanner system that includes a rotating gantry, a movable patient couch, and an operator console for control and image reconstruction; a Spectral Reconstruction System; and a Spectral CT Viewer. On the gantry, the main active components are the X-ray high voltage (HV) power supply, the X-ray tube, and the detection system.

The design/fundamental scientific technology of the proposed Spectral CT system and the currently marketed primary predicate device, Spectral CT system (K203020) and recently cleared secondary predicate device Spectral CT 7500 RT system (K240844) are the same. The design changes (e.g. new software version and additional software features) do not change the fundamental scientific technology of the proposed Spectral CT system.

The following table 1 lists the technological characteristics differences for the proposed Spectral CT system:

Table 01 Modifications made to the proposed device, Spectral CT system as compared to the currently marketed primary predicate device, Spectral CT system (K203020)

Design FeatureDescription
Pulmonary Gating 4DCTPulmonary gated scanning is a new feature that allows CT scan data to be collected along with the patient's breathing signal in order to allow the CT data to be reconstructed into specific phases of breathing. This allows patient anatomy to be visualized during a breathing cycle usually to allow for breathing motion of both the target as well as organs at risk to be compensated for during radiation therapy treatment planning.
Extended Field of View (EFOV)EFOV is a feature that allows for a maximum reconstructed FOV of up to 800mm for non-gated Helical scans only.

Page 8

Table 2 – Technological Characteristics Comparison

Design FeatureCurrently Marketed Primary Predicate Device: Spectral CT system (K203020)Currently approved Secondary Predicate Device: Spectral CT 7500 RT system (K240844)Proposed Device: Spectral CT systemConclusion
Design and Fundamental Scientific Technology
ApplicationHead, Body and CardiacHead, Body and CardiacHead, Body and CardiacIdentical, therefore substantially equivalent.
Scan regimeContinuous RotationContinuous RotationContinuous RotationIdentical, therefore substantially equivalent.
Scan Field of ViewUp to 500 mmUp to 800 mmUp to 800 mmSubstantially Equivalent. Both the proposed device and the primary predicate device include a Scannable Field of View (SFOV) of 500mm used for reconstructed images. The improvement of the FOV in the proposed device for up to 800mm (Extended Field of View (EFOV)) is planned for Radiation Therapy Planning procedure and is identical from a technology perspective to the recently cleared secondary predicate device, Spectral CT 7500 RT (K240844). The SFOV was successfully verified and validated and does not raise new questions on safety and/or effectiveness.
No. of slicesUp to 128 slices of 0.625 mmUp to 128 slices of 0.625 mmUp to 128 slices of 0.625 mmIdentical, therefore, substantially equivalent
Scan modesSurview, Axial-after-Axial Dynamic Scan, Helical ScanSurview, Axial-after-Axial Dynamic Scan, Helical ScanSurview, Axial-after-Axial Dynamic Scan, Helical ScanIdentical, therefore, substantially equivalent
Spatial Resolution16 lp/cm max (high mode), 13 lp/cm max (standard mode)16 lp/cm max (high mode), 13 lp/cm max (standard mode)16 lp/cm max (high mode), 13 lp/cm max (standard mode)Identical, therefore, substantially equivalent

Page 9

Design FeatureCurrently Marketed Primary Predicate Device: Spectral CT system (K203020)Currently approved Secondary Predicate Device: Spectral CT 7500 RT system (K240844)Proposed Device: Spectral CT systemConclusion
Minimum Scan time0.18 sec for 240° rotation, 0.27 sec for 360° rotation0.18 sec for 240° rotation, 0.27 sec for 360° rotation0.18 sec for 240° rotation, 0.27 sec for 360° rotationIdentical, therefore, substantially equivalent
Scan coverageScanner Center of Rotation (COR) is up to 80 mmScanner Center of Rotation (COR) is up to 80 mmScanner Center of Rotation (COR) is up to 80 mmIdentical, therefore, substantially equivalent
Low contrast resolution (32cm body CTDI phantom)4 mm @ 0.3% @ 25 mGy CTDIvol4 mm @ 0.3% @ 25 mGy CTDIvol4 mm @ 0.3% @ 25 mGy CTDIvolIdentical, therefore, substantially equivalent
Noise in (as standard mode measured on 21.6 cm water-equivalent)0.27% at 27 mGy0.27% at 27 mGy0.27% at 27 mGyIdentical, therefore, substantially equivalent
Image MatrixUp to 1024 x 1024Up to 1024 x 1024Up to 1024 x 1024Identical, therefore, substantially equivalent
Display1024 x 12801024 x 12801024 x 1280Identical, therefore, substantially equivalent
CommunicationCompliance with DICOM 3.0Compliance with DICOM 3.0Compliance with DICOM 3.0Identical, therefore, substantially equivalent
Detectors
TypeNano Panel PrismNano Panel PrismNano Panel PrismIdentical, therefore, substantially equivalent
MaterialSolid-state yttrium-based scintillator, GOS + PhotodiodeSolid-state yttrium-based scintillator, GOS + PhotodiodeSolid-state yttrium-based scintillator, GOS + PhotodiodeIdentical, therefore, substantially equivalent
DMS Detector Spectral CT 75008 cm - Dual-Layer scintillator, up to 128 detector rows8 cm - Dual-Layer scintillator, up to 128 detector rows8 cm - Dual-Layer scintillator, up to 128 detector rowsIdentical, therefore, substantially equivalent
DMS structureSpherical DMS structureSpherical DMS structureSpherical DMS structureIdentical, therefore, substantially equivalent
Collimation0.625 mm and various combinations, such as:0.625 mm and various combinations, such as:0.625 mm and various combinations, such as:Identical, therefore, substantially equivalent

Page 10

Design FeatureCurrently Marketed Primary Predicate Device: Spectral CT system (K203020)Currently approved Secondary Predicate Device: Spectral CT 7500 RT system (K240844)Proposed Device: Spectral CT systemConclusion
2x0.625, 16x0.625, 32x0.625, 64x0.625, 96x0.625, 112x0.625, 128x0.625 mm2x0.625, 16x0.625, 32x0.625, 64x0.625, 96x0.625, 112x0.625, 128x0.625 mm2x0.625, 16x0.625, 32x0.625, 64x0.625, 96x0.625, 112x0.625, 128x0.625 mm
Gantry
Gantry rotation speed0.27 sec -1.5 sec (360° rotation), 0.18 sec, 0.2 sec (240° rotation)0.27 sec -1.5 sec (360° rotation), 0.18 sec, 0.2 sec (240° rotation)0.27 sec -1.5 sec (360° rotation), 0.18 sec, 0.2 sec (240° rotation)Identical, therefore, substantially equivalent
Bore size800 mm800 mm800 mmIdentical, therefore, substantially equivalent
Operator Controls located on GantryTouch Panel ControlsTouch Panel ControlsTouch Panel ControlsIdentical, therefore, substantially equivalent
Eclipse CollimationA-PlaneA-PlaneA-PlaneIdentical, therefore, substantially equivalent
Generator and Tube Performance
Power120kW120kW120kWIdentical, therefore, substantially equivalent
kV Setting• 80 • 100 • 120 • 140• 80 • 100 • 120 • 140• 80 • 100 • 120 • 140Identical, therefore, substantially equivalent
mA Range10-100010-100010-1000Identical, therefore, substantially equivalent
Couch
CouchNoah CouchNoah CouchNoah CouchIdentical, therefore, substantially equivalent
Couch Vertical RangeMinimum Height – 430 mmMinimum Height – 430 mmMinimum Height – 430 mmIdentical, therefore, substantially equivalent
Couch Horizontal Range-2143 mm-2143 mm-2143 mmIdentical, therefore, substantially equivalent
Scannable Surview Range1940mm1940mm1940mmIdentical, therefore, substantially equivalent

Page 11

Design FeatureCurrently Marketed Primary Predicate Device: Spectral CT system (K203020)Currently approved Secondary Predicate Device: Spectral CT 7500 RT system (K240844)Proposed Device: Spectral CT systemConclusion
Scannable axial Range2000mm2000mm2000mmIdentical, therefore, substantially equivalent
Scannable helical Range1900mm1900mm1900mmIdentical, therefore, substantially equivalent
Couch Speed Range1 mm/sec – 600 mm/sec1 mm/sec – 600 mm/sec1 mm/sec – 600 mm/secIdentical, therefore, substantially equivalent
Acceleration800 mm/Sec^2800 mm/Sec^2800 mm/Sec^2Identical, therefore, substantially equivalent
Couch Max Load CapacityHigh Performance: 675 lbs. (307 kg), Utilizing RTP flat tabletop optional accessory: 628 lbs. (285 kg)High Performance: 675 lbs. (307 kg), Utilizing RTP flat tabletop optional accessory: 628 lbs. (285 kg)High Performance: 675 lbs. (307 kg), Utilizing RTP flat tabletop optional accessory: 628 lbs. (285 kg)Identical, therefore, substantially equivalent
Couch accessoriesInfant Cradle, Paper roller, Varian Camera Adaptor, Oncology flat tabletopInfant Cradle, Paper roller, Varian Camera Adaptor, Oncology flat tabletopInfant Cradle, Paper roller, Varian Camera Adaptor, Oncology flat tabletopIdentical, therefore, substantially equivalent
Clinical Applications: Dose Tools
Cardiac reconstruction methodStandard ECG Gated Reconstruction method, Motion Compensated Reconstruction (MCR) (optional feature)Standard ECG Gated Reconstruction method, Motion Compensated Reconstruction (MCR) (optional feature)Standard ECG Gated Reconstruction method, Motion Compensated Reconstruction (MCR) (optional feature)Identical, therefore substantially equivalent.
Virtual Tilt Viewer (VTV) (optional feature)YesYesYesIdentical, therefore substantially equivalent.
Pulmo & 4DCT (Four- Dimension Computed Tomography)NoYesYesSubstantially Equivalent. The proposed device, Spectral CT system introduces Pulmonary gated scanning which allows image acquisition of the esophagus and abdomen area while the patient is breathing. The Pulmonary gated scan

Page 12

Design FeatureCurrently Marketed Primary Predicate Device: Spectral CT system (K203020)Currently approved Secondary Predicate Device: Spectral CT 7500 RT system (K240844)Proposed Device: Spectral CT systemConclusion
feature is planned for Radiation Therapy Planning procedures and is similar from a technological perspective to the secondary recently marketed secondary predicate device, Spectral CT 7500 RT system (K240844). The Pulmonary gating was successfully verified and validated and does not raise new questions on safety and/or effectiveness
General
Technical Basis for Collection of two CT SpectralDual Layer DMS (Spectral Detector)Dual Layer DMS (Spectral Detector)Dual Layer DMS (Spectral Detector)Identical, therefore, substantially equivalent
Spectral Base ImagesLow energy, High-energy, Photoelectric, Compton ScatterLow energy, High-energy, Photoelectric, Compton ScatterLow energy, High-energy, Photoelectric, Compton ScatterIdentical, therefore, substantially equivalent
Spectral results available [kVp]100kVp, 120kVp, 140kVp100kVp, 120kVp, 140kVp100kVp, 120kVp, 140kVpIdentical, therefore, substantially equivalent
Spectral Results ImagesMonoenergetic, Materials Basis/Density Pairs, such as I / H20, I / Ca, Ca / Uric Acid, Effective Atomic Number, Material Separation/ Differentiation, Attenuation Curves, Density Measurements/VisualizationMonoenergetic, Materials Basis/Density Pairs, such as I / H20, I / Ca, Ca / Uric Acid, Effective Atomic Number, Material Separation/ Differentiation, Attenuation Curves, Density Measurements/VisualizationMonoenergetic, Materials Basis/Density Pairs, such as I / H20, I / Ca, Ca / Uric Acid, Effective Atomic Number, Material Separation/ Differentiation, Attenuation Curves, Density Measurements/VisualizationIdentical, therefore, substantially equivalent

Page 13

Design FeatureCurrently Marketed Primary Predicate Device: Spectral CT system (K203020)Currently approved Secondary Predicate Device: Spectral CT 7500 RT system (K240844)Proposed Device: Spectral CT systemConclusion
Reduction of Beam Hardening, Reduction of Calcium Blooming, Calcium Suppression Index, Electron Density, Spectral results for CardiacReduction of Beam Hardening, Reduction of Calcium Blooming, Calcium Suppression Index, Electron Density, Spectral results for CardiacReduction of Beam Hardening, Reduction of Calcium Blooming, Calcium Suppression Index, Electron Density, Spectral results for Cardiac
Host Drives256GB OS disk Plus one 7.68TB PCIE NVMe SSD256GB OS disk plus one 7.68TB PCIE NVMe SSD256GB OS disk plus one 7.68TB PCIE NVMe SSDIdentical, therefore, substantially equivalent
Host InfrastructureWindows 10Windows 10Windows 10Identical, therefore, substantially equivalent
CIRS ComputersCIRS Rack that contains two HP Z8 servers. Option for two additional HP Z8 Servers in the same rackCIRS Rack that contains two HP Z8 servers. Option for two additional HP Z8 Servers in the same rackCIRS Rack that contains two HP Z8 servers. Option for two additional HP Z8 Servers in the same rackIdentical, therefore, substantially equivalent
CIRS CPUsIn each HP Z8: Dual Intel Gold 6230 with 20 cores at 2.1GHz each.In each HP Z8: Dual Intel Gold 6230 with 20 cores at 2.1GHz each.In each HP Z8: Dual Intel Gold 6230 with 20 cores at 2.1GHz each.Identical, therefore, substantially equivalent
CIRS DrivesIn each HP Z8: 512GB NVMe SSD for OS and CIRS software, Two 2TB NVMe SSDs for raw data.In each HP Z8: 512GB NVMe SSD for OS and CIRS software, Two 2TB NVMe SSDs for raw data.In each HP Z8: 512GB NVMe SSD for OS and CIRS software, Two 2TB NVMe SSDs for raw data.Identical, therefore, substantially equivalent

Page 14

Design FeatureCurrently Marketed Primary Predicate Device: Spectral CT system (K203020)Currently approved Secondary Predicate Device: Spectral CT 7500 RT system (K240844)Proposed Device: Spectral CT systemConclusion
Interventional ControlsYesYesYesIdentical, therefore, substantially equivalent

Based on the information provided above, the proposed Spectral CT system is considered substantially equivalent to the currently marketed primary predicate device, Spectral CT system (K203020), in terms of fundamental scientific technology.

Page 15

Summary of Non-Clinical Performance Data

Non-clinical performance testing has been performed on the proposed Spectral CT system and demonstrates compliance with the following International and FDA recognized consensus standards and FDA guidance document(s): (e.g., see below)

  • IEC 60601-1:2005 A1:2012 A2:2020: Medical electrical equipment -- Part 1: General requirements for safety and essential performance (FDA recognition number: 19-49).
  • IEC 60601-1-2:2014 A1:2020: Medical electrical equipment -- Part 1-2: General requirements for safety - Collateral standard: Electromagnetic compatibility - Requirements and tests (FDA recognition number: 19-36).
  • IEC 60601-1-3:2008 A2:2021: Medical electrical equipment -- Part 1: General requirements for safety -- 3. Collateral standard: General requirements for radiation protection in diagnostic X-ray equipment. (FDA recognition number: 12-336).
  • IEC 60601-1-6:2010 A1:2013 A2:2020: Medical electrical equipment -- Part 1-6: General requirements for safety - Collateral standard: Usability (FDA recognition number: 5-132).
  • IEC 60601-2-28:2017: Medical Electrical Equipment - Part 2: Particular Requirements for the Safety of X-ray Source Assemblies and X-ray Tube Assemblies for Medical Diagnosis (FDA recognition number: 12-309).
  • IEC 60601-2-44:2009 A1:2012 A2:2016: Medical electrical equipment -- Part 2-44: Particular requirements for the basic safety and essential performance of X-ray equipment for computed tomography (FDA recognition number: 12-302).
  • IEC 60825-1:2014 ISH1:2017 ISH2:2017: Safety measures, Light hazards, Lasers, Wavelengths, Eyes, Warning devices, Mathematical calculations, Medical equipment, Light emission, Marking, Hazards, Symbols, Instructions for use, Physiological effects (human body), Skin (body), Classification systems, Definitions, Occupational safety (FDA recognition number: 12-273).
  • IEC 62304:2006 + A1:2015: Medical device software - Software life-cycle processes (FDA recognition number: 13-79).
  • IEC 62366-1:2015 A1:2020: Medical devices - Application of usability engineering to medical devices (FDA recognition number: 5-129).
  • ISO 14971:2019: Medical devices - Application of risk management to medical devices (FDA recognition number: 5-125).
  • ISO 10993-1:2018: Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process (FDA recognition number: 2-258)

Device Specific Guidance Document:

  • Guidance for Industry and FDA Staff – Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices (issued May 11, 2005).
  • Guidance for Industry and FDA Staff – Content of Premarket Submissions for Device Software Functions (issued June 14, 2023).
  • Pediatric Information for X-ray Imaging Device Premarket Notifications – Guidance for Industry and Food and Drug Administration Staff (November 28, 2017)
  • Guidance for Industry and FDA Staff – Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions (issued September 27, 2023)
  • Guidance for Industry and FDA Staff – Design Considerations and Pre-market Submission Recommendations for Interoperable Medical Devices (issued September 6, 2017)

Design verification planning and testing were conducted at the system level. The system is tested against the System Requirements Specifications (SRS). System verification activities demonstrate the system meets the established system design input requirements.

The traceability between the requirements, the hazard mitigations, and the test protocols are described in the traceability matrix.

Page 16

Design Validation tests the user needs and intended use that are documented in the top-level User Requirement Specification (PRS). The validation testing covered new features, clinical validation, and serviceability validation. All the validation tests as per validation plan were performed and acceptance criteria met for each of the requirements.

Non-clinical design validation testing demonstrates that the proposed Spectral CT system can be used as defined in its clinical workflow and intended use.

All these tests were used to support substantial equivalence of the subject device and demonstrate that the proposed Spectral CT system:

  • Complies with the aforementioned international and FDA-recognized consensus standards and/or FDA guidance document, and;
  • Meets the acceptance criteria and is adequate for its intended use.

Summary of Clinical Performance Data

Therefore, the proposed Spectral CT system is substantially equivalent to the currently marketed primary predicate device, Spectral CT system (K203020), in terms of safety and effectiveness.

Substantial equivalence to the currently marketed primary predicate device Spectral CT system (K203020) and the cleared secondary predicate device Spectral CT 7500 RT system (K240844) were demonstrated through the following attributes:

  • Indication for use
  • Technological characteristics
  • Non-clinical performance testing
  • Clinical Image Evaluation
  • Safety and effectiveness

To support the evaluation of the new features, the submission includes:

  • Phantom-based image quality (IQ) testing, assessing parameters such as noise, resolution, and artifacts
  • A representative clinical image assessment
  • Comparison of performance data against internal performance requirements

This data supports the safety, effectiveness, and substantial equivalence of the subject device.

Substantial Equivalence Conclusion

The proposed Spectral CT system is substantially equivalent to the currently marketed primary predicate device, Spectral CT system (K203020) and currently cleared secondary predicate device Spectral CT 7500 RT system (K240844), in terms of indications for use, technological characteristics and principles of operation. The minor technological differences between the proposed Spectral CT system and currently marketed primary predicate device, Spectral CT system (K203020), raise no new issues of safety or effectiveness. Non-clinical performance data demonstrate that the proposed Spectral CT system performs as expected and in a manner that is substantially equivalent to its predicate device. Thus, the proposed Spectral CT system is substantially equivalent.